Search results
Results from the WOW.Com Content Network
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase;
chronic lymphocytic leukemia: Ceritinib [1] Novartis Pharmaceuticals: ALK-positive metastatic non-small cell lung cancer: Idelalisib [1] Gilead Sciences: relapsed chronic lymphocytic leukemia: Ibrutinib [1] Pharmacyclics: chronic lymphocytic leukemia (with 17p deletion Eltrombopag [1] Novartis Pharmaceuticals: aplastic anemia: Pembrolizumab [1 ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
[12] [4] The use of tobacco is also associated with an increased risk of having CLL. [10] Diagnosis is typically based on blood tests that find high numbers of mature lymphocytes and smudge cells. [5] This is an example of how a smudge cell looks on a peripheral blood smear, which is a common finding in patients with chronic lymphocytic ...
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. [2] For CLL it is a preferred treatment. [3] It is given by mouth. [3] Common side effects include bone marrow suppression. [3]
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
FDA-Approved Treatment: Sildenafil. Sildenafil, the generic form of Viagra, is a widely-used medication for ED that’s been approved since the late 1990s by the FDA.
In February 1991, Scripps began a collaboration with Johnson & Johnson to bring intravenous cladribine to market, and by December of that year, Johnson & Johnson had filed a new drug application; cladribine was approved by the FDA in 1993 for hairy cell leukemia as an orphan drug, [25] and was approved in Europe later that year. [26]: 2